SCHEMBL959668

SCHEMBL959668

COC(=O)N(CCCC(=O)c1ccc(F)cc1)[C@@H](C)c1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HTR7 P34969 1/20 0.43
HDAC1 Q13547 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
CYP2D6 P10635 2/20 0.40
NR1I2 O75469 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
CHRM3 P20309 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655071 0.93 KMT2A (0.39) NPC1RAB9AHTR7HDAC1HDAC8
SCHEMBL3655073 0.93 KMT2A (0.39) NPC1RAB9AHTR7HDAC1HDAC8
SCHEMBL3637292 0.87 NPC1 (0.47) NPC1RAB9AHTR7HDAC1HDAC8
SCHEMBL13077090 0.84 SLC6A4 (0.42) SLC6A2SLC6A4SLC6A3PDE6D
SCHEMBL960035 0.81 SMN1; SMN2 (0.45) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL1463908 0.81 NPC1 (0.37) NPC1RAB9AHTR7CYP2D6NR1I2
SCHEMBL1463909 0.81 NPC1 (0.37) NPC1RAB9AHTR7CYP2D6NR1I2
SCHEMBL956964 0.77 L3MBTL1 (0.39) KCNH2L3MBTL1KMT2A
SCHEMBL1463848 0.77 SMN1; SMN2 (0.38) NPC1RAB9AHDAC1HDAC8L3MBTL1
SCHEMBL16588239 0.77 ALOX5 (0.35) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals ,Inc. 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 NPC1 504/4885RAB9A 4131/4885HTR7 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.